Confidence is the currency of science.
IDT will be participating in AGBT 2021 virtually this year as one of the bronze sponsors. Your work is advancing science and helping people around the world. By partnering with researchers like you, we can build NGS solutions to fit your workflow seamlessly so you can get your projects started faster.
Visit IDT at the virtual booth and talk to an expert!
Facing a tough challenge in the lab? Have questions about our products? We’d love to help. During the conference, connect with an IDT expert one on one.
- M2GEN’s ORIEN Avatar® program accelerates the discovery, development, and delivery of comprehensive oncology research with a custom xGen™ Exome Research Panel
Dr. Oliver A. Hampton, Vice President of Bioinformatics and Biostatistics at M2GEN
Whole exome sequencing (WES) and targeted sequencing are widely accepted industry standards as powerful methods to discover potential causative variants that drive diseases such as cancer. WES’s clinical research applications include evaluating genetic sequences for therapeutic drug targeting or identifying biomarkers for clinical trial stratification and/or personalized treatment. Oncology research leverages WES of patients’ tumors to advance progress toward improved cancer diagnoses, prognoses, and personalized treatment. Thus, it is critical to obtain high-quality, high-confidence DNA sequences for calling somatic variants, which is achieved via the M2GEN ORIEN Avatar program migration from Roche SeqCap EZ Exome Probes to a custom xGen Exome Research Panel. The xGen panel uses a custom exome design to detect point mutations, amplifications, deletions, and translocations/structural variants in the full set of protein coding genes and therapeutically actionable non-coding regions, such as the TERT promoter and other common oncology translocation junctions. The xGen Exome Research Panel v1.0 is the backbone of the M2GEN ORIEN Avatar exome capture design. The panel targets the coding sequence of 19,396 human protein coding genes (39 Mb) composed of 429,826 xGen Lockdown™ Probes, providing consistent uniformity of coverage for tumor-normal sequencing. The custom portion of the exome probe set targets select oncology-actionable genes such as promoter, enhancer, and intronic regions for structural variant detection. IDT’s combination of high-performance xGen Lockdown Probes with the capability to easily spike-in custom capture content improves somatic mutation assessment of cancer patients’ tumors and aids M2GEN’s mission to accelerate the discovery, development, and delivery of more personalized therapies.
Explore some of our NGS solutions
xGen Prism DNA Library Prep Kit
xGen Exome Research Panel v2
NGS Discovery Pools
xGen Lockdown Probe Pools
xGen Lockdown Panels
xGen Blocking Oligos
Custom NGS Adapters